The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Integrative Omics to Enhance Therapeutics Development for Healthy Aging (UH2/UH3 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) is a phased innovation initiative to facilitate multi-omics/integrative approaches to identify omics profiles associated with protection against multiple aging conditions, with exceptional health span, and to refine strategies for utilizing these profiles for therapeutics development. Specifically, a phased innovation cooperative agreement mechanism (UH2/UH3) involving an interdisciplinary research team will be used to support a single project that will conduct integrative analysis of person-specific multiple omics measurements (e.g., transcriptomics, proteomics, metabolomics) generated across multiple tissues; the multi-omic profiling should be conducted on individuals from extensively phenotyped cohorts with substantial numbers of long-lived individuals with characteristics of exceptionally healthy aging and appropriate controls. It will also: 1) harmonize and extend the use of existing phenotypic data from these studies to apply phenomics to transcriptomic, proteomic, metabolomic findings; 2) select animal model species or strains with varying life spans for comparative omics studies and identify potential determinants of species differences in longevity and rates of disease development; 3) develop appropriate computational and analytical tools to identify omics profiles associated with exceptional longevity and healthy aging; 4) apply translational bioinformatics approaches and leverage existing publicly available drug signatures databases to identify molecules that could produce profiles associated with exceptionally healthy aging; and 5) exchange data with other NIH/NIA-supported related omics activities and other public-private partnerships (e.g., Trans-Omics for Precision Medicine (TOPMed), Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD)) for data harmonization and analysis.
- Letter of Intent Due Date(s): October 14, 2018
- Application Due Date(s): November 14, 2018
RFA-AG-19-011 Expiration Date November 15, 2018
Application budgets should not exceed $3.3 million in direct costs.
Applicants may request a total project period of up to 5 years. The maximum project period is 2 years for the UH2 phase and 3 years for the UH3 phase.